Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages

References

• Kaur MS, Garg T, Narang R. A review of emerging in the treatment of tuberculosis. Artif Cell Nanomed B. 2014;44:478–484.
   PubMed Web of Science ®Google Scholar
• WHO. Global tuberculosis report 2016. Switzerland: WHO Library Cataloguing-in-Publication Data; 2016.
   Google Scholar
• Cadena AM, Flynn JL, Fortune SM. The importance of first impressions: early events in Mycobacterium tuberculosis infection influence outcome. mBio. 2016;7:1–9.
   Web of Science ®Google Scholar
• Flynn JL, Chan J, Lin PL. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol. 2011;4:271–278.
   PubMed Web of Science ®Google Scholar
• Costa A, Pinheiro M, Magalhães J, et al. The formulation of nanomedicines for treating tuberculosis. Adv Drug Deliv Rev. 2016;102:102–115.
   PubMed Web of Science ®Google Scholar
• Kolyva AS, Karakousis PC. Old and new TB drugs: mechanisms of action and resistance, understanding tuberculosis – new approaches to fighting against drug resistance. London, UK: InTech; 2012.
   Google Scholar
• Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and management – an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015;3:220–234.
   PubMed Web of Science ®Google Scholar
• Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013;12:388–404.
   PubMed Web of Science ®Google Scholar
• Arun B, Narendar D, Veerabrahma K. Development of olmesartan medoxomil lipid-based nanoparticles and nansuspension: preparation, characterization and comparative pharmacokinetic evaluation. Artif Cell Nanomed B. 2017;46:126–137.
   PubMed Web of Science ®Google Scholar
• Radtke M, Souto EB, Muller RH. Nanostructured lipid carriers – a novel generation of solid lipid drug carriers. Pharm Technol Eur. 2015;17:45–50.
   Google Scholar
• Pinheiro M, Ribeiro R, Vieira A, et al. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des Devel Ther. 2016;10:2467–2475.
   PubMed Web of Science ®Google Scholar
• Irache JM, Salman HH, Gamazo C, et al. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv. 2008;5:703–724.
   PubMed Web of Science ®Google Scholar
• Ferreira M, Silva E, Barreiros L, et al. Methotrexate loaded lipid nanoparticles for topical management of skin-related diseases: design, characterization and skin permeation potential. Int J Pharm. 2016;512:14–21.
   PubMed Web of Science ®Google Scholar
• Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148:359–367.
   PubMed Web of Science ®Google Scholar
• Vieira AC, Chaves LL, Pinheiro M, et al. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells. Int J Nanomedicine. 2016;11:2601–2617.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Eskandari S, Tabbakhian M. Freeze-drying of nanostructure lipid carriers by different carbohydrate polymers used as cryoprotectants. Carbohydr Polym. 2012;88:1157–1163.
   Web of Science ®Google Scholar
• Olena I, Emerson C, Barbara P, et al. Influence of silver content on rifampicin adsorptivity for magnetite/Ag/rifampicin nanoparticles. Nanotechnology. 2017;28:055603.
   PubMed Web of Science ®Google Scholar
• Pinheiro M, Pisco S, Silva AS, et al. Evaluation of the effect of rifampicin on the biophysical properties of the membranes: significance for therapeutic and side effects. Int J Pharm. 2014;166:190–197.
   Web of Science ®Google Scholar
• Shah RM, Bryant G, Taylor M, et al. Structure of solid lipid nanoparticles produced by a microwave-assisted microemulsion technique. RSC Adv. 2016;6:36803–36810.
   Web of Science ®Google Scholar
• Singh SK, Dadhania P, Vuddanda PR, et al. Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment. RSC Adv. 2016;6:2032–2045.
   Web of Science ®Google Scholar
• Barros D, Costa Lima SA, Cordeiro-da-Silva A. Surface functionalization of polymeric nanospheres modulates macrophage activation: relevance in leishmaniasis therapy. Nanomedicine (Lond). 2015;3:387–403.
   Web of Science ®Google Scholar
• Cho M, Cho WS, Choi M, et al. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett. 2009;189:177–183.
   PubMed Web of Science ®Google Scholar
• Chow AH, Tong HH, Chattopadhyay P, et al. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411–437.
   PubMed Web of Science ®Google Scholar
• Neves AR, Lúcio M, Martins S, et al. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine. 2013;8:177–187.
   PubMed Web of Science ®Google Scholar
• Müller H, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;23:3–19.
   Web of Science ®Google Scholar
• Silva AC, Kumar A, Wild W, et al. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Pharm. 2012;436:798–805.
   PubMed Web of Science ®Google Scholar
• Vivek K, Reddy H, Murthy RSR. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2007;8:16–24.
   PubMed Web of Science ®Google Scholar
• Andreani T, Kiill CP, de Souza ALR, et al. Surface engineering of silica nanoparticles for oral insulin delivery: characterization and cell toxicity studies. Colloids Surf B Biointerfaces. 2014;123:916–923.
   PubMed Web of Science ®Google Scholar
• Yamori S, Ichiyama S, Shimokata K, et al. Bacteriostatic and bactericidal activity of antituberculosis drugs against Mycobacterium tuberculosis, Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium kansasii in different growth phases. Microbiol Immunol. 1992;36:361–368.
   PubMed Web of Science ®Google Scholar
• Chai GH, Hu FQ, Sun J, et al. Transport pathways of solid lipid nanoparticles across Madin − Darby canine kidney epithelial cell monolayer. Mol Pharm. 2014;11:3716–3726.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MÁ, Gascón AR, et al. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166:115–123.
   PubMed Web of Science ®Google Scholar
• Lopes-de-Araújo J, Neves AR, Gouveia VM, et al. Oxaprozin-loaded lipid nanoparticles towards overcoming NSAIDs side-effects. Pharm Res. 2016;33:301–134.
   PubMed Web of Science ®Google Scholar
• Neves AR, Queiroz JF, Costa Lima SA, et al. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: relevance for oral drug delivery. J Colloid Interface Sci. 2016;463:258–265.
   PubMed Web of Science ®Google Scholar
• Moretton MA, Chiappetta DA, Andrade F, et al. Hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages. J Biomed Nanotechnol. 2013;9:1076–1087.
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145:182–195.
   PubMed Web of Science ®Google Scholar
• Ruge CA, Hillaireau H, Grabowski N, et al. Pulmonary surfactant protein A-mediated enrichment of surface-decorated polymeric nanoparticles in alveolar macrophages. Mol Pharmaceutics. 2016;13:4168–4178.
   PubMed Web of Science ®Google Scholar
• Zvaritch E, Lambeau G, Lazdunski M. Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2. J Biol Chem. 1996;271:250–225.
   PubMed Web of Science ®Google Scholar
• Linehan SA, Martinez-Pomares L, da Silva RP, et al. Endogenous ligands of carbohydrate recognition domains of the mannose receptor in murine macrophages, endothelial cells and secretory cells; potential relevance to inflammation and immunity. Eur J Immunol. 2001;31:1857–1866.
   PubMed Web of Science ®Google Scholar